Abstract: According to various aspects of this disclosure, the present disclosure relates to a fusion protein comprising a truncated complement receptor 1 (CR1) protein or a functional fragment thereof. In some aspects, the fusion protein further comprises a complement receptor 2 (CR2) protein or a functional fragment thereof. Certain aspects of this disclosure relate to an adeno-associated virus (AAV) vector comprising a polynucleotide comprising a promoter operably linked to a nucleic acid encoding a CR2-CRI fusion protein. Other aspects of this disclosure relate to a method of treating a subject suffering from a complement-mediated disorder, the method comprising administering any of the fusion proteins disclosed herein or any of the AAV vectors disclosed herein.

Abstract: Provided herein are peptide-based therapeutics that target POXP3 and methods of use thereof to decrease the immunosuppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.

Abstract: Provided herein are peptide-based therapeutics that target FOXP3 and methods of use thereof to decrease the immuno-suppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.

Abstract: Disclosed herein are recombinant adeno-associated viral vectors expressing 21-hydroxy lase (21OH) protein and related uses for treating 21OH deficiency.

Abstract: Provided herein are peptide-based therapeutics that target FOXP3 and methods of use thereof to decrease the immunosuppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.